Iriyama Noriyoshi, Miura Katsuhiro, Takahashi Hiromichi, Nakagawa Masaru, Iizuka Kazuhide, Otake Shimon, Hamada Takashi, Koike Takashi, Kurihara Kazuya, Endo Toshihide, Nakamura Hideki
Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.
Department of Hematology and Rheumatology, National Hospital Organization Saitama Hospital, Saitama, Japan.
J Clin Exp Hematop. 2025 Jun 28;65(2):93-100. doi: 10.3960/jslrt.25010. Epub 2025 May 30.
This study investigates the outcomes of patients with peripheral T-cell lymphoma (PTCL) treated with a doxorubicin-based regimen (CHOP) and a pirarubicin-based regimen (THP-COP). Newly diagnosed patients with PTCL between 2001 and 2021 were classified by initial treatment, either CHOP or THP-COP regimen. The treatment response, event-free survival (EFS), and overall survival (OS) were assessed. Overall, 65 patients were analyzed, with 41 classified into the CHOP group and 24 into the THP-COP group. Dose-intensified regimen was applied in 22 patients (53.7%) in the CHOP group and 16 (66.7%) in the THP-COP group. When stratified by treatment, the complete response (CR) rates in the CHOP group and the THP-COP group were 66% and 46% (P = 0.273), the 3-year EFS rates were 52.1% and 29.2% (P = 0.0492), and the 3-year OS rates were 72.7% and 48.6% (P = 0.0718), respectively. When stratified by treatment intensity, the CR rates in the dose-intensified group and the conventional dose group were 65% and 50% (P = 0.230), the 3-year EFS rates were 45.9% and 39.6% (P = 0.995), and the 3-year OS rates were 61.1% and 66.4% (P = 0.267), respectively. This study revealed no significant advantage of the THP-COP regimen over the CHOP regimen regarding treatment outcomes for newly diagnosed PTCLs.
本研究调查了接受基于阿霉素的方案（CHOP）和基于吡柔比星的方案（THP-COP）治疗的外周T细胞淋巴瘤（PTCL）患者的预后。2001年至2021年新诊断的PTCL患者按初始治疗分类，即CHOP或THP-COP方案。评估治疗反应、无事件生存期（EFS）和总生存期（OS）。总体而言，分析了65例患者，其中41例分类为CHOP组，24例分类为THP-COP组。CHOP组22例患者（53.7%）和THP-COP组16例患者（66.7%）应用了剂量强化方案。按治疗分层时，CHOP组和THP-COP组的完全缓解（CR）率分别为66%和46%（P = 0.273），3年EFS率分别为52.1%和29.2%（P = 0.0492），3年OS率分别为72.7%和48.6%（P = 0.0718）。按治疗强度分层时，剂量强化组和常规剂量组的CR率分别为65%和50%（P = 0.230），3年EFS率分别为45.9%和39.6%（P = 0.995），3年OS率分别为61.1%和66.4%（P = 0.267）。本研究显示，对于新诊断的PTCLs，THP-COP方案在治疗结果方面并不比CHOP方案有显著优势。
